Research Article
Role of Paricalcitol in Modulating the Immune Response in Patients with Renal Disease
Table 2
Production in vitro of NGAL and inflammatory cytokines.
| (a) CKD patients |
| | | Before paricalcitol | After paricalcitol | | | PBMC + PHA | PBMC | PBMC + PHA | PBMC | | (10 μg/mL) | (10 μg/mL) |
| | IL-17 (pg/mL) | 39 ± 6.2 | <15 | 19 ± 3.8 | <15 | | IL-6 (pg/mL) | 66 ± 9.8 | <1.4 | 31 ± 5.9 | <1.4 | | IFN-γ (pg/mL) | 174 ± 32.9 | <1.5 | 78 ± 11.7 | <1.5 | | IL-1β (pg/mL) | 97 ± 13.3 | <1 | 42 ± 4.3 | <1 | | TNF-α (pg/mL) | 202 ± 31.4 | <1.6 | 104 ± 15.8 | <1.6 | | NGAL (ng/mL) | 78 ± 9.2 | <0.1 | 21 ± 4.1 | <0.1 |
|
|
| (b) HS |
| | | PBMC + PHA | PBMC | | (10 μg/mL) |
| | IL-17 (pg/mL) | 21 ± 2.9 | <15 | | IL-6 (pg/mL) | 32 ± 4.2 | <1.4 | | IFN-γ (pg/mL) | 59 ± 7.9 | <1.5 | | IL-1β (pg/mL) | 43 ± 7.1 | <1 | | TNF-α (pg/mL) | 97 ± 13.9 | <1.6 | | NGAL (ng/mL) | 16 ± 3.1 | <0.1 |
|
|
CKD: chronic kidney disease; HS: healthy subjects; NGAL: neutrophil gelatinase associated lipocalin; IL-17: interleukin-17; IL-6: interleukin-6; IL-1β: interleukin-1 beta; IFN-γ: interferon-gamma; TNF-α: tumor necrosis factor-alpha.
|
